Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling.

Andreia Barroso, João V Mahler, Pedro H Fonseca-Castro, Francisco J Quintana

Current opinion in immunology 2021 Jun

filter terms:

Dendritic cells (DCs) are potent antigen-presenting cells (APCs), which sample the exogenous and endogenous cues to control adaptive immunity, balancing effector and regulatory components of the immune response. Multiple subsets of DCs, such as plasmacytoid and conventional DCs, have been defined based on specific phenotypic markers, functions and regulatory transcriptional programs. Tolerogenic DCs (tolDCs) have been functionally defined based on their ability to expand the regulatory T-cell compartment and suppress immune responses. However, it is still unclear whether tolDCs represent a homogeneous population, a specific DC subset and/or a heterogeneous collection of DC activation/maturation states. The ligand-activated transcription factor aryl hydrocarbon receptor (AHR) has been shown to control transcriptional programs associated to tolDCs. In this review, we discuss the role of AHR in the control of tolDCs, and also AHR-targeted approaches for the therapeutic induction of tolDCs in autoimmune diseases and allergy. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Andreia Barroso, João V Mahler, Pedro H Fonseca-Castro, Francisco J Quintana. Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling. Current opinion in immunology. 2021 Jun;70:33-39